NCT00837291View on ClinicalTrials.gov

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 30, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

January 31, 2019

Conditions

Osteoarthritis of the Knee

Interventions

DRUG

CF101

CF101 tablets 1 mg BID

DRUG

Placebo

Placebo tablets BID

Trial Locations (1)

Unknown

Barzilai Medical Center, Ashkelon

Sponsors

Lead Sponsor

Can-Fite BioPharma

All Listed Sponsors

lead

Can-Fite BioPharma

INDUSTRY